Podcast: Abpro Chairman & CEO Ian Chan and Shahraab Ahmad, Chairman & CEO of Atlantic Coastal II (ACAB)
by Kristi Marvin on 2024-03-13 at 7:42am

Developing new medical treatments takes time and money, which is generally where investors come in. But, has managed to resolve many of those questions before SPAC investors will join the show.

This week, we speak with Abpro Chairman and CEO Ian Chan and Shahraab Ahmad, Chairman and CEO of Atlantic Coastal Acquisition Corp II (Nasdaq: ACAB). The two announced a $725 million dollar combination in September 2023.

Shahraab explains how Abpro came onto Atlantic Coastal II’s radar after the SPAC had originally been fishing in the mobility space, and why the particularities of its capital needs could be a fit for the current market conditions.

Ian also walks through Abpro’s clinical path moving forward and how it can use a mix of its internal discovery engines and M&A to expand its portfolio.

Give it a listen.



 

Recent Posts
by Nicholas Alan Clayton on 2025-05-13 at 1:07pm

Jena II (NYSE:JENAU) has filed for a $200 million SPAC that brings serial SPAC leader William P. Foley II and his team back into the ring. This pedigree is clear in the terms the team has been able to command with just one right to a 1/20 share in each unit and 24 months to...

by Nicholas Alan Clayton on 2025-05-13 at 8:24am

At the SPAC of Dawn Investors are set to get an update on Core CPI inflation readings this morning as de-SPACs continue to report on operational advances alongside their first quarter earnings. Among them, eVTOL developer Archer (NYSE:ACHR) noted that it is on track to deliver its first Midnight aircraft to the UAE in the...

by Nicholas Alan Clayton on 2025-05-12 at 5:17pm

Perimeter Acquisition Corp. I (NASDAQ:PMTRU) announced the pricing of its upsized $210 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “PMTRU”, Tuesday, May 13, 2025. The new SPAC aims to combine with a target company with that can contribute to the re-industrialization of the United States economy,...

by Nicholas Alan Clayton on 2025-05-12 at 1:14pm

Horizon Space II (NASDAQ:HSPT) has signed a definitive agreement to combine with clinical stage biotech firm SL Bio Ltd. for $5.57 billion in equity consideration. Taipei, Taiwan-based SL Bio is developing drug candidates to treat several cancer types while also selling over-the-counter beauty products derived from natural extracts. The combined company is expected to trade...

by Nicholas Alan Clayton on 2025-05-12 at 8:17am

At the SPAC of Dawn This is set to be a slower week for votes with just two SPACs seeking an extension and none yet scheduling a meeting for approving a business combination. Integrated Rail & Resources (OTC:IRRX) primed the pump somewhat for investors ahead of its Tuesday special meeting by announcing it has entered...

logo

Copyright © 2025 SPACInsider, Inc. All Rights Reserved